Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)
Open Access
- 5 August 2010
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 151 (2), 143-151
- https://doi.org/10.1111/j.1365-2141.2010.08331.x
Abstract
To assess if immunochemotherapy influenced the prognostic value of IPI in elderly diffuse large B‐cell lymphoma (DLBCL) patients, we evaluated the performance of the standard International Prognostic Index (IPI) and following modifications: age adjusted (AA)‐IPI, revised (R)‐IPI, and an elderly IPI with age cut‐off 70 years (E‐IPI) in patients >60 years treated with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). In 267 patients, by IPI/AA‐IPI 60% were high‐intermediate, 53% high and 12% low risk. With R‐IPI, 60% were poor risk and none very good risk. Using E‐IPI, 45% were high‐intermediate/high risk and 27% low risk. No differences in outcome were seen in the low/low‐intermediate groups with IPI/AA‐IPI. For E‐IPI, failure‐free survival (FFS) and overall survival (OS) were significantly different for low/low‐intermediate groups. No differences were detected in the four indices with model fit/discrimination measures; however, E‐IPI ranked highest. For elderly R‐CHOP treated patients, distribution of IPI/AA‐IPI skewed toward high/high‐intermediate risk with no differences in FFS/OS between low/low‐intermediate risk. In contrast, with E‐IPI, more are classified as low risk with significant differences in FFS/OS for low‐intermediate compared to low risk. The R‐IPI does not identify a very good risk group, thus minimizing its utility in this population. The prognostic discrimination provided by the E‐IPI for low and low‐intermediate elderly DLBCL patients needs validation by other datasets.This publication has 32 references indexed in Scilit:
- Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPBlood, 2008
- Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapyBlood, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Cancer and age in the USACritical Reviews in Oncology/Hematology, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958